Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05009550
Other study ID # 2021/346
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date May 15, 2021
Est. completion date September 1, 2021

Study information

Verified date August 2021
Source TC Erciyes University
Contact Özlem OZ Gergin, MD
Phone 09005332466396
Email oozgergin@erciyes.edu.tr
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To evaluate the ability of Erector spina Plane Block decrease postoperative pain and analgesia requirements in patients undergoing percutaneous Radiofrequency ablation of Hepatocellular Carcinomas.


Description:

Erector spina Plane Block is performed with guided ultrasound at T8 transverse process level lead to adequate intraprocedural and postoperative analgesia, in percutaneous Radiofrequency ablation of Hepatocellular Carcinomas.


Recruitment information / eligibility

Status Recruiting
Enrollment 30
Est. completion date September 1, 2021
Est. primary completion date September 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria: - ASA I-II patients Exclusion Criteria: - history of allergy to the study medication - refused to participate

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
Group ESP
Single-shot ultrasound guided ESP block is performed at the T8 vertebral level before the procedure to all patients in ESP block Group
Other:
Non-blocked Group
This Group is received no intervention.Patients will be sedated as standard and radiofrequency procedure will be applied.

Locations

Country Name City State
Turkey Özlem Öz Gergin Kayseri

Sponsors (1)

Lead Sponsor Collaborator
TC Erciyes University

Country where clinical trial is conducted

Turkey, 

References & Publications (2)

Joung KW, Choi SS, Jang DM, Kong YG, Lee HM, Shim JH, Won HJ, Shin YM, Kim PN, Song MH. Comparative Effects of Dexmedetomidine and Propofol on US-Guided Radiofrequency Ablation of Hepatic Neoplasm Under Monitored Anesthesia Care: A Randomized Controlled S — View Citation

Wells SA, Hinshaw JL, Lubner MG, Ziemlewicz TJ, Brace CL, Lee FT Jr. Liver Ablation: Best Practice. Radiol Clin North Am. 2015 Sep;53(5):933-71. doi: 10.1016/j.rcl.2015.05.012. Review. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Numeric Pain Scale assesment A research assistant, blinded to the group allocation, interviewed patients and collected data at 6 times intervals (0.,2.,4.,6.,12 and 24 hours) in the 24 hours postprocedure. Patients will be asked to rate their pain using Numeric Pain Scale, where 0=no pain and 10=worst pain possible. 24 hours after procedure
Secondary Demographic data Age, BMI, ASA, Duration of procedure are recorded. 24 hours after procedure
Secondary Incidences of adverse effects (like nausea and vomiting) Incidences of adverse effects (like nausea and vomitting) during the 24 hours postprocedure perIod is recorded at 6 times intervals (0,2,4,6,12,24 hours) 24 hours after procedure
See also
  Status Clinical Trial Phase
Recruiting NCT03253250 - The Investigation of Peginterferon Alfa-2a on the RFS of the Subjects With HCC Who Have Been Treated by Resection Phase 4
Terminated NCT01760616 - Huaier Granule for Prevention of Disease Progression of Hepatocarcinoma After Non-radical Hepatectomy Phase 4
Active, not recruiting NCT04682847 - Radiotherapy With Iron Oxide Nanoparticles (SPION) on MR-Linac for Primary & Metastatic Hepatic Cancers
Not yet recruiting NCT03149523 - Exhaustive Genetic and Immunological Characterization of Colon, Kidney and Liver Tumors N/A
Recruiting NCT06342414 - An Exosome-Based Liquid Biopsy for the Differential Diagnosis of Primary Liver Cancer
Recruiting NCT03132740 - Impact of Three-dimensional Visualization on Operation Strategy and Complications for Complex Hepatic Carcinoma
Completed NCT03164382 - Hepatic Arterial Infusion of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib in Advanced Hepatocellular Carcinoma Phase 3
Completed NCT03572582 - Transarterial Chemoembolization in Combination With Nivolumab Performed for Intermediate Stage Hepatocellular Carcinoma Phase 2
Completed NCT04266548 - Arterial Base Fluorescence Segmental Positive Staining N/A
Recruiting NCT03013712 - A Clinical Research of CAR T Cells Targeting EpCAM Positive Cancer Phase 1/Phase 2
Recruiting NCT01350726 - Functional-three-dimensional Reconstruction of Liver by 99MTc-GSA-SPECT Scan N/A
Completed NCT06245798 - Liver Resection for Patients With Hepatocellular Carcinoma and Clinically Significant Portal Hypertension
Recruiting NCT06311396 - Development of a Neuronal Microscope N/A
Recruiting NCT04220944 - Combined Locoregional Treatment With Immunotherapy for Unresectable HCC. Phase 1
Completed NCT02352935 - Percutaneous Irreversible Electroporation for Unresectable Hepatic Carcinoma in Poor Liver Function N/A
Completed NCT02332551 - Percutaneous Irreversible Electroporation to Treat Liver Cancer Close to the Gallbladder N/A
Completed NCT02834780 - Phase 1 Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of H3B-6527 in Participants With Advanced Hepatocellular Carcinoma Phase 1
Not yet recruiting NCT06182865 - A Study of Ga-68 Dolacga to Evaluate Liver Reserve Function in Patients With HCC Before and After Proton Therapy N/A
Completed NCT05007548 - to Assess the Accuracy and Reliability of the Ga68-Dolacga Positron Emission Tomography Compared to Computer Tomography Volumetry and Indocyanine Green Retention Test for Measurement of Liver Reserve Phase 2
Completed NCT03163186 - Transradial Versus Transfemoral Arterial Access in Liver Cancer Embolization: Randomized Trial to Assess Patient Outcomes and Satisfaction (BEST ACCESS Trial). N/A